Abstract
The Indian pharmaceutical industry is at the crossroads due to the recognition of the product patent in the amended Patent Act of 2005 and the gradual liberalization policy of the government of India. While the recognition of product patents is a big challenge for Indian pharmaceutical companies that have hitherto relied on imitation for their growth, the liberalization of the market economy has also opened up new opportunities for Indian pharmaceutical firms. In response to policy changes and growing competition, firms started adopting new strategies like increased outlays in R&D related activities, endeavors to sell their product in the global market and investment in plant and machinery. However, the benefit from such change may not be immediate. Also, when access to resources and technology differs across firms, the process of liberalization may create winners and losers and performance differences may widen between firms.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Majumdar M and M Rajeev (2009b) Comparing the Efficiency and Productivity of the Indian Pharmaceutical Firms: A Malmquist–Meta-Frontier Approach International Journal of Business and Economics 8(2) 159–181.
Mazumdar M, Rajeev M (2007) TRIPS Agreement and the Emerging In-house R & D Activity of the Indian Pharmaceutical Companies: A panel Data Analysis of the Firm Level Data. PES Business Review 3(1):3–23
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2013 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Mazumdar, M. (2013). Conclusions and Policy Suggestions. In: Performance of Pharmaceutical Companies in India. Contributions to Economics. Physica, Heidelberg. https://doi.org/10.1007/978-3-7908-2876-4_8
Download citation
DOI: https://doi.org/10.1007/978-3-7908-2876-4_8
Published:
Publisher Name: Physica, Heidelberg
Print ISBN: 978-3-7908-2875-7
Online ISBN: 978-3-7908-2876-4
eBook Packages: Business and EconomicsBusiness and Management (R0)